Ardelyx is trading at $3.04, down 5.00%, amid biotech-sector weakness, the clearest available explanation; XBI is down 2.08% in the regular session.
- Broader markets were mixed: the Dow was down 0.97%, the S&P 500 down 0.27%, and the Nasdaq up 0.06%.
- A securities class action announced October 23 alleges prior investor disclosures understated commercial access challenges; available reporting does not establish that it caused the intraday move. Third-quarter results are scheduled for November 3.